Pacira BioSciences Showcases Real-World Studies at AMCP Nexus
Pacira BioSciences Prepares for AMCP Nexus 2025
Pacira BioSciences, Inc. (NASDAQ: PCRX), a leader in non-opioid pain management, has announced the upcoming presentation of new data at the AMCP Nexus 2025 Annual Meeting. This event, occurring in late October, will highlight important findings from three real-world studies regarding EXPAREL® (bupivacaine liposome injectable suspension), showcasing the clinical and economic advantages of the innovative therapy.
Real-World Evidence from New Studies
At the AMCP Nexus 2025, the company will unveil significant real-world evidence gathered through its Innovations in Genicular Outcomes Registry (IGOR), which offers a comprehensive view of the effectiveness of EXPAREL in managing postsurgical pain.
According to Jennifer Lin, Senior Director of Health Economics and Outcomes Research at Pacira, the aim is to enhance understanding around postsurgical pain management and decrease reliance on opioids. This mission reflects a broader commitment within healthcare to seek alternative pain management options that prioritize patient safety.
Key Presentations at AMCP Nexus 2025
Innovative Approaches to Pain Management
The presentations by Pacira at the AMCP Nexus will focus on:
- Intraoperative Liposomal Bupivacaine's Impact: This study reveals how the use of liposomal bupivacaine can lead to improved patient outcomes, including lower opioid consumption and reduced healthcare costs following total knee arthroplasty. Presenter: Jennifer Lin.
- Outcomes for Medicare Patients: An analysis contrasting clinical and health economic outcomes for outpatient shoulder arthroplasty patients with and without liposomal bupivacaine, highlighting the efficacy of non-opioid therapies in a Medicare population. Presenter: Gabriel Wong.
- Resource Utilization in Ambulatory Surgical Centers: This investigation into healthcare resources and costs associated with total knee arthroplasty reveals crucial insights into the financial benefits of employing EXPAREL for pain management. Presenter: Gabriel Wong.
Understanding EXPAREL® (bupivacaine liposome injectable suspension)
EXPAREL represents a breakthrough in postsurgical pain management, providing long-lasting analgesia with the potential to significantly reduce opioid consumption. By utilizing a sustained release formula, EXPAREL allows for effective pain control, greatly enhancing recovery experiences for patients undergoing various surgical procedures.
This innovative product is currently approved for use in various surgical blocks, including interscalene brachial plexus block and sciatic nerve block. It sets a new standard for pain management in the postoperative setting.
Commitment to Patient Safety and Efficacy
Pacira is dedicated to delivering safe and effective novel therapies that minimize the risks associated with traditional opioid medications. With the alarming rise of opioid dependence and misuse, companies like Pacira are paving the way for alternative solutions that ensure patients manage pain without the associated risks of addiction.
Moreover, Pacira is advancing the development of PCRX-201 (enekinragene inzadenovec), aiming for solutions in the treatment of prevalent diseases such as osteoarthritis, signaling its ongoing commitment to expanding its product offerings and addressing unmet medical needs.
Conclusion
As the healthcare landscape continues to evolve, the role of companies like Pacira BioSciences becomes increasingly significant. Presenting at AMCP Nexus 2025 is not only an opportunity for Pacira to share their findings but also to engage in essential discussions about the future of pain management. By continuing to focus on innovative, non-opioid treatments, Pacira aims to transform patient care and outcomes for those in need of effective pain relief.
Frequently Asked Questions
What is EXPAREL®?
EXPAREL is a long-acting local analgesic used for postsurgical pain management, helping to reduce opioid reliance.
Where will the presentations be held?
The presentations will take place at the AMCP Nexus 2025 Annual Meeting.
Who are the presenters from Pacira BioSciences?
Key presenters include Jennifer Lin and Gabriel Wong, who will present important findings from recent studies.
What is the objective of the studies presented?
The studies aim to evaluate the effectiveness and cost benefits of using EXPAREL in managing pain after surgical procedures.
How does Pacira contribute to opioid use reduction?
By advancing non-opioid pain therapies, Pacira is committed to minimizing the dependency on opioid prescriptions for pain management.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.